Literature DB >> 1156516

The influence of tumour burden and therapy on cellular cytotoxicity responses in patients with ocular and skin melanoma.

B Unsgaard, C O'Toole.   

Abstract

Using a microassay for cellular immunity, tumour specific cytotoxicity was detected in 2/5 cases of ocular melanoma and 1/3 cases of primary cutaneous melanoma before treatment. Reactivity was measured against allogeneic skin melanoma target cells in short or long term in vitro culture. Lymphoid cells from patients with disseminated cutaneous melanoma were either non-reactive (4/8 cases) or gave a nonspecific cytotoxicity on target cells of diverse histogenic origins. Among tumour-free patients tested after surgery, 0/2 patients with ocular tumour were non-reactive 3-4 months post surgery. After sugical excision of cutaneous melanoma 2/2 patients gave tumour specific reactions during the first month after surgery. After longer time intervals, from 5 months to 3 years, only 1/8 patients were reactive. Preoperative radiotherapy in a total skin dose of 10,000 rad produ-ed a transient tumour specific reaction 24 h after therapy in a single case. Following local tumour excision in patients given preoperative irradiation, 2 cases which had previously demonstrated tumour specific CMI lost reactivity. Among 14 tumour-free individuals tested only after preoperative radiotherapy and surgery, at intervals from 5 day to 13 years, a single case gave tumour specific CMI. Palliative irradiation in doses 4000-4960 rad to the inguinal or axillary lymph nodes was found to induce a generalized lymphopenia within 48 h after treatment. Lymphoid cell preparations from patients with localized melanoma contained significantly increased numbers of immature cells (lymphoblasts and myeloblasts) and myeloid precursor elements. Those prepared from patients with disseminated disease had in addition elevated levels of eosinophils but reduced numbers of recoverable lymphocytes.

Entities:  

Mesh:

Year:  1975        PMID: 1156516      PMCID: PMC2009427          DOI: 10.1038/bjc.1975.65

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  SEPARATION OF VIABLE LYMPHOCYTES FROM HUMAN BLOOD.

Authors:  A S COULSON; D G CHALMERS
Journal:  Lancet       Date:  1964-02-29       Impact factor: 79.321

2.  A new method for preparing buffy coat-poor blood.

Authors:  T J GREENWALT; M GAJEWSKI; J L McKENNA
Journal:  Transfusion       Date:  1962 Jul-Aug       Impact factor: 3.157

3.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

Authors:  J Bubeník; M Baresová; V Viklický; J Jakoubková; H Sainerová; J Donner
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  Some recent studies on cellular immunity to human melanomas.

Authors:  I Hellström; K E Hellström
Journal:  Fed Proc       Date:  1973-02

5.  Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma.

Authors:  J Stjernswärd; M Jondal; F Vánky; H Wigzell; R Sealy
Journal:  Lancet       Date:  1972-06-24       Impact factor: 79.321

6.  Cellular immunity to human urinary bladder carcinoma. II. EEffect of surgery and preoperative irradiation.

Authors:  C O'Toole; P Perlmann; B Unsgaard; L E Almgård; B Johansson; G Moberger; F Edsmyr
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

7.  In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma.

Authors:  U W Jehn; L Nathanson; R S Schwartz; M Skinner
Journal:  N Engl J Med       Date:  1970-08-13       Impact factor: 91.245

8.  Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy.

Authors:  C O'Toole; P Perlmann; B Unsgaard; G Moberger; F Edsmyr
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

9.  Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors:  D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

Review 10.  Immune factors in human cancer: malignant melanomas, skeletal and soft tissue sarcomas.

Authors:  D L Morton; F R Eilber; R A Malmgren
Journal:  Prog Exp Tumor Res       Date:  1971
View more
  5 in total

1.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence.

Authors:  H Koho; S Paulie; H Ben-Aissa; I Jónsdóttir; Y Hansson; M L Lundblad; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Influence of surgery and dexamethasone on cell-mediated immune responses in patients with meningiomas.

Authors:  H W Pees
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

3.  Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition.

Authors:  J H Marti; D M Thomson
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

4.  The natural history of antitumour immunity in human breast cancer assayed by tube leucocyte adherence inhibition.

Authors:  M Lopez; R O'Connor; J K MacFarlane; D M Thomson
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

5.  Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma.

Authors:  C O'Toole; Z H Price; Y Ohnuki; B Unsgaard
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.